Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.

ABSTRACT:

Objective

To assess whether bezafibrate increases fatty acid oxidation (FAO) and lowers heart rate (HR) during exercise in patients with carnitine palmitoyltransferase (CPT) II and very long-chain acyl-CoA dehydrogenase (VLCAD) deficiencies.

Methods

This was a 3-month, randomized, double-blind, crossover study of bezafibrate in patients with CPT II (n = 5) and VLCAD (n = 5) deficiencies. Primary outcome measures were changes in FAO, measured with stable-isotope methodology and indirect calorimetry, and changes in HR during exercise.

Results

Bezafibrate lowered low-density lipoprotein, triglyceride, and free fatty acid concentrations; however, there were no changes in palmitate oxidation, FAO, or HR during exercise.

Conclusion

Bezafibrate does not improve clinic

SUBMITTER: Orngreen MC 

PROVIDER: S-EPMC3963421 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature